Acutus Medical (AFIB) AI Stock Analysis

• Market Cap: $14.96K
• Dividend Yield: N/A
• Average Volume (3M): 20.94K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.38
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 29,912,306
• 10 Day Avg. Volume: 19,516
• 30 Day Avg. Volume: 20,944
• PEG Ratio: <0.01
• Price to Book (P/B): -0.14
• Price to Sales (P/S): 0.08
• P/FCF Ratio: -0.05
• Enterprise Value/Market Cap: 1.56K
• Enterprise Value/Revenue: 1.16
• Enterprise Value/Gross Profit: 23.30
• Enterprise Value/Ebitda: 10.40
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: $0.00 ▼(-100.00% Downside)

Acutus Medical's overall stock score is primarily impacted by its poor financial performance and valuation metrics. The company is unprofitable with negative cash flows and a highly leveraged balance sheet, posing significant investment risks. Technical analysis also indicates bearish momentum, further weighing on the stock's prospects.

Acutus Medical Business Overview & Revenue Model

Company Description

Acutus Medical, Inc. is a medical technology company focused on developing innovative solutions for the diagnosis and treatment of cardiac arrhythmias, particularly atrial fibrillation (AFIB). The company operates in the cardiovascular sector, offering advanced electrophysiology tools and mapping systems that enhance the precision and efficiency of cardiac procedures. Its core products include the AcQMap® system, which provides real-time, high-resolution mapping of the heart, and various catheter devices designed for use in ablation procedures.

How the Company Makes Money

Acutus Medical generates revenue primarily through the sale of its medical devices and systems used in electrophysiology procedures. The company’s revenue model includes direct sales of its AcQMap® systems and disposable catheters to hospitals and clinics. Additionally, Acutus may benefit from recurring revenues associated with the sale of consumables used in conjunction with its systems. The company also explores partnerships with healthcare providers and distributors to expand its market reach, and it may enter into collaborations with other medical technology firms to enhance its product offerings and drive sales growth.

Acutus Medical Financial Statement Overview

Summary

Acutus Medical faces significant financial challenges with unprofitable operations, negative margins, and a highly leveraged balance sheet. The company is struggling to maintain financial stability, as indicated by the negative cash flows and insolvency risk highlighted in the financial statements.

Income Statement

Acutus Medical has shown some improvement in total revenue over the years, but the company still struggles with negative profitability. The gross profit margin has only recently turned positive, but net profit margin remains deeply negative, indicating ongoing challenges in managing expenses relative to revenues. The EBIT and EBITDA margins are also negative, reflecting continued operational losses.

Balance Sheet

The company's balance sheet reveals high leverage with a negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is not calculable due to negative equity, but the overall liabilities exceed assets, suggesting insolvency risk. Return on equity cannot be calculated due to negative equity, further highlighting financial instability.

Cash Flow

Acutus Medical's cash flow statement shows consistent negative operating cash flows, impacting the company's ability to generate positive free cash flow. The free cash flow growth rate is not applicable due to the consistent negative cash flow figures. The operating cash flow to net income ratio is unfavorable, highlighting inefficiencies in converting operations to cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.16M	7.16M	3.03M	17.26M	8.46M
Gross Profit	1.01M	-3.14M	-1.91M	-15.66M	-7.42M
EBITDA	2.25M	-5.33M	35.20M	-105.12M	-92.55M
Net Income	-9.55M	-81.66M	-39.62M	-117.68M	-101.98M
Balance Sheet
Total Assets	28.65M	53.96M	133.44M	169.79M	192.53M
Cash, Cash Equivalents and Short-Term Investments	14.02M	22.40M	70.45M	100.77M	131.07M
Total Debt	35.76M	38.48M	38.86M	45.40M	41.08M
Total Liabilities	40.24M	54.84M	58.42M	64.07M	65.95M
Stockholders Equity	-11.59M	-879.00K	75.02M	105.73M	126.58M
Cash Flow
Free Cash Flow	-31.77M	-63.34M	-89.02M	-109.66M	-96.39M
Operating Cash Flow	-31.66M	-63.12M	-85.03M	-99.68M	-85.17M
Investing Cash Flow	22.15M	58.55M	104.75M	19.07M	-63.82M
Financing Cash Flow	-2.89M	-2.66M	-12.12M	79.57M	164.43M

Acutus Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLPT	―	$540.12M	―	-85.68%	―	19.68%	-13.17%
ECOR	―	$40.30M	―	-210.58%	―	30.16%	22.51%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PAVM	―	$10.67M	0.34	―	―	-73.36%	―
RCEL	―	$100.62M	-1.92	-935.73%	―	38.32%	-1.31%
COCH	―	$24.05M	―	―	―	-26.49%	-91.23%
AFIB	―	$14.96K	―	406.89%	―	―	―

Acutus Medical Corporate Events

Acutus Medical Restructures Workforce Amid Strategic Shift

Acutus Medical has announced a significant downsizing, reducing its workforce by 70% to focus solely on fulfilling obligations to Medtronic for left-heart access products. This strategic move aims to cut costs while leveraging potential earnout payments from Medtronic until 2027. The transition will include operational changes and a shift in CEO and CFO roles, with the company continuing to support Medtronic through contract manufacturing. The downsizing is expected to be largely complete by Q1 2025.